Chang J, Zhang W, Lin G, et al. - Researchers performed this retrospective analysis to determine the function of IL-10 in chemotherapy drug resistance in metastatic colorectal cancer (mCRC). An oxaliplatin-containing or irinotecan-containing regimen was administered to all 264 mCRC patients included in the study. Experts assessed the expression level of IL-10 in the plasma of 232 patients and the tumor tissue of 68 patients. They found that treatment with a chemotherapeutic regimen resulted in a significant rise in IL-10 level. In univariate and multivariate Cox proportional hazard analyses, it was revealed that low IL-10 concentration in plasma was significantly related to improved overall survival of mCRC patients who received therapy with irinotecan-containing regimen-with optimal cutoff value of 5.525pg/mL, respectively. Based on findings, experts suggested IL-10 could be a prognostic biomarker for mCRC patients receiving irinotecan-containing chemotherapy.